Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders

Cancer Discovery

Volumn 5, Issue 1, 2015, Pages 64-71

  Hyman, David M ^a   Diamond, Eli L ^a   Vibat, Cecile Rose T ^b   Hassaine, Latifa ^b   Poole, Jason C ^b   Patel, Minal ^a   Holley, Veronica R ^c   Cabrilo, Goran ^c   Lu, Timothy T ^b   Arcila, Maria E ^a   Chung, Young Rock ^a   Rampal, Raajit ^a   Lacouture, Mario E ^a   Rosen, Neal ^a   Meric Bernstam, Funda ^c   Baselga, José ^a   Kurzrock, Razelle ^d   Erlander, Mark G ^b   Janku, Filip ^c   Abdel Wahab, Omar ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Trovagene Inc   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GENOMIC DNA; VEMURAFENIB; B RAF KINASE; CODON;

ADOLESCENT; ADULT; AGED; ARTICLE; B RAF GENE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DNA EXTRACTION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; ERDHEIM CHESTER DISEASE; FEMALE; GENE MUTATION; GENOTYPE; HISTIOCYTOSIS; HUMAN; LANGERHANS CELL HISTIOCYTOSIS; MALE; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYSTEMIC HISTIOCYTIC DISORDER; TREATMENT RESPONSE; URINALYSIS; AMINO ACID SUBSTITUTION; BIOPSY; CODON; CROSS-SECTIONAL STUDY; ERDHEIM-CHESTER DISEASE; GENE FREQUENCY; GENETICS; HISTIOCYTOSIS, LANGERHANS-CELL; MIDDLE AGED; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; POSITRON EMISSION TOMOGRAPHY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; BIOPSY; CHILD; CODON; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; ERDHEIM-CHESTER DISEASE; FEMALE; GENE FREQUENCY; GENES, RAS; GENOTYPE; HISTIOCYTOSIS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS B-RAF; YOUNG ADULT;

EID: 84922372527     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0742     Document Type: Article

References (23)

1. Janku F, Munoz J, Subbiah V, Kurzrock R. A tale of two histiocytic disorders. Oncologist 2013; 18: 2- 4.
2. Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, et al. BRAFV600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014; 211: 669- 83.
3. Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-Cin E, Campochiaro C, et al. BRAF V600E mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis 2014 Mar 26. [Epub ahead of print].
4. Badalian-Very G, Vergilio J-A, Degar B, MacConaill L, Brandner B, Calicchio M, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116: 1919-23.
5. Arnaud L, Bach G, Zeitoun D, Drier A, Cluzel P, Grenier PA, et al. Whole-body MRI in Erdheim-Chester disease. Rheumatology 2012; 51: 948-50.
6. Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE 2012; 7: e33891.
7. Sahm F, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka F, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012; 120: e28- 34.
8. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013; 121: 1495-500.
9. Hyman DM, Blay J-Y, Chau I, Raje NS, Fernandez MEE, Wolf J, et al. VEBASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). J Clin Oncol 2014; 32: 5s (suppl; abstr 2533).
10. Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014; 124: 483- 92.
11. Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio- Net. Orphanet J Rare Dis 2013; 8: 72.
12. Janku F, Vibat CR, Kosco T, Holley K, Cabrilo VR, Meric-Bernstam G, et al. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget 2014; 5: 3607- 10.
13. Arcila M, Lau C, Nafa K, Ladanyi M. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011; 13: 64-73.
14. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-31.
15. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. New York: Chapman & Hall; 1984.
16. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol 2006; 24: 167-75.
17. Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010; 116: 4070- 6.
18. Emile JF, Diamond EL, Helias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 2014 Aug 22. [Epub ahead of print].
19. Diamond EL, Abdel-Wahab O, Pentsova E, Borsu L, Chiu A, Teruya- Feldstein J, et al. Detection of an NRAS mutation in Erdheim- Chester disease. Blood 2013; 122: 1089-91.
20. Casadio V, Calistri D, Salvi S, Gunelli R, Carretta E, Amadori D, et al. Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. Bio Med Res Int 2013; 2013: 270457.
21. Casadio V, Calistri D, Tebaldi M, Bravaccini S, Gunelli R, Martorana G, et al. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol 2013; 31: 1744-50.
22. Zhang SH, Zhao SM, Zhao ZM, Li CT. Genotyping of urinary samples stored with EDTA for forensic applications. Genet Mol Res 2012; 11: 3007-12.
23. Chan KC, Yeung SW, Lui WB, Rainer TH, Lo YM. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem 2005; 51: 781-4.